GLD3-Glucose Dehydrogenase

Added to your cart

GLD3-Glucose Dehydrogenase

Cart subtotal: £0.00

View cart (0) Checkout

#SKU GLD3

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

BBI Solutions offers a next generation FAD-dependent GlucoseDehydrogenase (FAD-GDH). FAD-GDH with reduced xylose interference is part of our market leading range of enzymes for blood glucose monitoring, it reduces cross reactivity with a range of sugars, provides increased specificity to glucose and improves reactivity and stability. Our two grades of FAD-GDH (GLD1 and GLD3), offer proven performance in a range of systems, the decision on which one’s right for you will depend on your individual platform.
GLD3

More information

Attributes

Description

  • Abbreviations
  • GLD, GDH
  • Lead Time
  • 6 weeks
  • Storage
  • Store desiccated at -15°C or below. Allow to come
  • Shelf Life
  • 6 months
  • Manufacturer Country
  • UK
  • Presentation Matrix
  • A yellow freeze dried material.
  • Source
  • Microorganism
  • Activity
  • ≥300 U/mg material
  • EC Number
  • 1.1.99.10
  • Solubility
  • Dissolves readily at 5mg/ml in 0.05M potassium phosphate buffer, pH 5.6 to give a clear solution.
  • Systematic Name
  • D-Glucose: (flavin adenine dinucleotide) dehydrogenase

Technical Documents

GLD3 Product Specification (55.08KB)

Product Specification (55.08KB)

Product Information (313.4KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox